{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.65","upperLimit":"18.14","value":"14.32"},{"groupId":"OG001","lowerLimit":"3.61","upperLimit":"55.10","value":"36.27"},{"groupId":"OG002","lowerLimit":"3.68","upperLimit":"20.21","value":"10.45"},{"groupId":"OG003","lowerLimit":"17.71","upperLimit":"34.40","value":"26.68"},{"groupId":"OG004","lowerLimit":"8.57","upperLimit":"18.89","value":"13.44"},{"groupId":"OG005","lowerLimit":"13.04","upperLimit":"25.66","value":"17.45"},{"groupId":"OG006","lowerLimit":"9.69","upperLimit":"20.67","value":"15.64"},{"groupId":"OG007","lowerLimit":"11.07","upperLimit":"22.90","value":"15.24"},{"groupId":"OG008","lowerLimit":"8.71","upperLimit":"19.25","value":"13.96"},{"groupId":"OG009","lowerLimit":"9.43","upperLimit":"54.83","value":"22.24"},{"groupId":"OG010","lowerLimit":"7.62","upperLimit":"16.39","value":"12.48"},{"groupId":"OG011","lowerLimit":"7.43","upperLimit":"30.52","value":"12.75"},{"groupId":"OG012","lowerLimit":"4.37","upperLimit":"10.51","value":"7.85"},{"groupId":"OG013","lowerLimit":"13.11","upperLimit":"32.20","value":"20.21"},{"groupId":"OG014","lowerLimit":"15.15","upperLimit":"36.50","value":"22.11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"57"},{"groupId":"OG005","value":"50"},{"groupId":"OG006","value":"51"},{"groupId":"OG007","value":"61"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"50"},{"groupId":"OG010","value":"49"},{"groupId":"OG011","value":"49"},{"groupId":"OG012","value":"49"},{"groupId":"OG013","value":"36"},{"groupId":"OG014","value":"35"}],"units":"Participants"}],"description":"OS is defined as the time from randomization date or first dosing date of study medication to the date of death (due to any cause). Participants who were alive were censored at the last known alive dates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG004","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG006","title":"Cohort 2 HBV Infected: Treatment 4"},{"description":"Arm A: Advance hepatocellular carcinoma (HCC) participants received nivolumab 240 mg every 2 weeks","id":"OG007","title":"Cohort 3: Treatment 1"},{"description":"Arm B: Advance hepatocellular carcinoma (HCC) participants received Sorafenib 400 mg twice a day","id":"OG008","title":"Cohort 3: Treatment 2"},{"description":"Arm A: Participants received nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks","id":"OG009","title":"Cohort 4: Treatment 1"},{"description":"Arm B: Participants received nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","id":"OG010","title":"Cohort 4: Treatment 2"},{"description":"Arm C: Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks","id":"OG011","title":"Cohort 4: Treatment 3"},{"description":"Participants received nivolumab 240 mg every 2 weeks","id":"OG012","title":"Cohort 5: Treatment 1"},{"description":"Participants received nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily","id":"OG013","title":"Cohort 6: Treatment 1"},{"description":"Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks + cabozantinib 40 mg once daily","id":"OG014","title":"Cohort 6: Treatment 2"}],"paramType":"MEDIAN","populationDescription":"All treated participants for Cohort 1, 2, and 5, and all randomized participants for Cohort 3, 4 and 6. Uninfected HCC, HCV-infected, and HBV-infected participants were pre-specified to be reported together for Cohort 1.","reportingStatus":"POSTED","timeFrame":"From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of death or date last known alive (up to approximately 144 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}